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ABSTRACT
Introduction: Opioid-induced constipation
(OIC) is the most common side effect of
opioid treatment. Treatment for OIC typically
involves a laxative. However, some patients
have an inadequate response to these (laxative
inadequate responders, or LIR). This has led to
the development of treatments such as
naloxegol. This analysis estimates the impact
of naloxegol on the health state utility of LIR
patients, examines if this utility impact is
driven by the change in OIC status, and
estimates the utility impact of relief of OIC.
Methods: The analysis was conducted using
data from two 12-week randomized controlled
trials, KODIAC 4 (ClinicalTrials.gov identifier,
NCT01309841) and KODIAC 5
(ClinicalTrials.gov identifier, NCT01323790),
plus KODIAC 7 (ClinicalTrials.gov identifier,
NCT01395524), a 12-week extension to
KODIAC 4. All were designed to assess the
efficacy and safety of oral naloxegol (12.5 and
25 mg) compared to placebo. Health state
utility data were collected through the
EuroQol—five dimensions questionnaire
(EQ-5D-3L). Descriptive analysis was
undertaken to estimate how EQ-5D utility
scores and EQ-5D domain responses varied
with treatment, OIC status, and over time. A
repeated measure mixed-effects model was used
to predict the change from baseline in health
state utility score over time.
Results: Compared with placebo, LIR patients
treated with naloxegol 25 mg reported a 0.08
improvement in the EQ-5D overall score after
12 weeks of treatment. The analyses also suggest
that change in OIC status is a key driver of the
impact of OIC treatment on health state utility.
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When other factors are controlled, relieving
OIC is associated with a 0.05 improvement in
health state utility, although treatment with
naloxegol is associated with an improvement in
health state utility over and above the
improvement in OIC status.
Conclusion: These analyses suggest that
treatment with naloxegol improves patients’
health state utility; driven predominantly by
the relief of patients’ constipation.
Funding: AstraZeneca.
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INTRODUCTION
Chronic pain is a symptom that accompanies
many conditions including joint pain,
fibromyalgia, and osteoarthritis [1, 2]. In
industrialized countries, opioids are frequently
used alternatives for the treatment of
moderate-to-severe chronic nonmalignant
pain, second only to nonsteroidal
anti-inflammatory agents in terms of
prescription frequency [3–6]. A total of 365
million opioid prescriptions were made globally
in 2005 [1]. One in five people in Europe suffer
from moderate-to-severe chronic non-cancer
pain; 25–30% of those are prescribed opioids
[3, 4, 7, 8]. One in four people in the United
States (US) suffer from moderate-to-severe
chronic non-cancer pain, and 15–20% of those
groups are prescribed opioids [7, 9, 10]. Chronic
non-cancer pain affects a quarter of the
Canadian population, a third of which are
prescribed strong opioids [11, 12].
Opioid-induced constipation (OIC) is the
most common side effect of opioid treatment
in patients with cancer and non-cancer pain,
and all patients using opioids are at risk of
developing OIC [1]. OIC typically begins within
the first few days of starting an opioid
treatment, and although some patients may
experience some relief with dose reduction of
the opioid, it typically persists for over the
treatment duration [1, 13].
The effects of OIC can cause psychological
distress, bodily suffering, and social isolation
[1, 14, 15]. The symptoms of OIC include rectal
and/or lower abdominal pain, abdominal
distension, straining during evacuation,
bloating, and flatulence [16–18]. Stool
impaction is a potential outcome of OIC that
occurs when retained stools form large, firm
lumps that are impossible to defecate, which in
turn may lead to bowel obstruction, stercoral
ulcers, and urinary retention [19]. This stage of
OIC necessitates manual disimpaction or even
surgery. Psychological distress is caused by OIC
as a result of the general distress about the
constipation itself as well as depressive
symptoms and anticipatory anxiety, which
may increase over time [16, 20]. The
symptoms of OIC have a considerable negative
impact on activities of daily living [1, 14]. It has
been reported that constipation is even more
common source of distress than the pain
originally being treated [21]. In some patients,
OIC becomes so severe that patients may taper
or even discontinue opioid use in an attempt to
relieve their discomfort, as they prefer
tolerating their pain rather than suffering from
continued bowel dysfunction
[1, 14, 15, 18, 22–24]. Moreover, in contrast to
other opioid-induced side effects (e.g., nausea),
patients rarely develop a tolerance to OIC
[1, 14, 17].
Utilities are one particular measure of
HRQoL used in economic evaluations,
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representing preferences for states of health,
measured on a scale of 0 [death] to 1 [perfect
health] [25]. A number of studies have
demonstrated low health state utility values
for patients with OIC. For instance, a
cross-sectional survey of OIC patients in the
US, Canada, Germany, and the United Kingdom
(UK) estimated that the mean European Quality
of Life (EuroQol)—Five Dimensions
questionnaire (EQ-5D) index score was 0.49
and the mean EQ-5D Visual Analogue Scale
score was 50.6, measured on a scale of 0 [death]
to 100 [perfect health] [2]. These EQ-5D values
suggest that patients with OIC have lower
utility than patients with conditions, such as
myocardial infarction, minor stroke, chronic
obstructive pulmonary disease, some
high-incidence cancers, and even some
end-stage cancers, such as prostate and
colorectal cancer (mean EQ-5D range of
0.55–0.76) [26–31].
The low health state utility values in patients
with OIC are most likely a result of both the
chronic pain and the side effects of opioid
treatment including OIC. For instance, patients
with chronic lower back pain report EQ-5D
scores ranging between 0.53 and 0.64 [32, 33],
and those with chronic cancer pain who
required constipation therapy had a mean
EQ-5D score of 0.49 [34]. To quantify the
impact of OIC on a patients’ health state
utility, a comparison between patients with
and without OIC, but who previously had
OIC, is required. There is, however, limited
published evidence of the impact of OIC on
health state utility. A paper by Penning van
Beest et al. estimated the EQ-5D in patients with
a severe non-curable disease treated with
opioids, and found that utility was much
higher in those who were constipated than
not constipated (0.65 vs. 0.31, respectively)
[26]. However, this difference seems
unreasonably large, and the study suffers from
a number of limitations. It focused on
constipation, in general, in opioid users, rather
than OIC specifically, and the definition of
constipation adopted by the study relied on
self-reports of constipation and laxative use.
Most importantly, the study was cross-sectional
and not designed to assess the causal impact of
OIC on health state utility and did not control
for other factors that may influence this.
The importance of research to generate
quantitative estimates of the impact of OIC on
health state utility is underscored by the limited
efficacy of standard of care for OIC. Laxatives
are typically used as an initial treatment option
for OIC in clinical practice; however, studies
report between 81% and 94% of patients who
take laxatives to treat their OIC exhibited an
inadequate response [2, 14, 35]. It is evident
therefore that OIC remains a significant issue
for pain management with the large proportion
of patients who are laxative inadequate
responders (LIR), showing a clear unmet need
[2].
Patients are likely to have an inadequate
response to laxatives because laxatives do not
target the mu-opioid receptors to which opioids
bind in the gastrointestinal (GI) tract. Opioids
disrupt normal motility, sphincter function,
and intestinal fluid secretion into the lumen,
potentially leading to OIC [36]. This has led to
the use of pharmacological agents that work to
specifically block the effect of opioids on the GI
tract and prevent OIC from occurring,
including nonselective opioid antagonists and
peripherally acting mu-opioid receptor
antagonists (PAMORAs) [19].
Naloxegol is a once daily treatment and is
the first oral PAMORA that has been approved
in the European Union for OIC. Naloxegol was
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studied in two, three arm, randomized,
controlled, double-blind pivotal trials,
KODIAC 4 and KODIAC 5, comparing
naloxegol 12.5 mg, naloxegol 25 mg, and
placebo in chronic non-cancer pain patients.
The primary outcome in both studies was the
response to study drug, defined as 3 or more
spontaneous bowel movements (SBMs) per
week and a change from baseline of 1 or more
SBM per week for at least 9 out of the 12 study
weeks and 3 out of the preceding 4 study weeks.
Naloxegol 25 mg, the dose for which naloxegol
received approval, was associated with
significantly higher response rates in LIR
patients compared with placebo over 12 weeks
trials (KODIAC 4, 48.7% vs. 28.8%; KODIAC 5,
46.8% vs. 31.4%) [37].
The objective of the present analysis was to
generate rigorous estimates of the impact of
once daily 25 mg dose of naloxegol on the
health state utility of LIR patients, the
population for whom naloxegol has received
market authorization in the EU; to examine if
this utility impact of naloxegol is driven
primarily by the change in OIC status, or
whether the treatment has an impact beyond
its impact on OIC status; and lastly to examine
the utility impact of relief of OIC.
METHODS
Data Sources
The KODIAC trial program was designed to
assess the efficacy and safety of naloxegol 12.5
and 25 mg in adult patients with OIC with the
EQ-5D being collected in three studies in the
program. The primary objective of both
KODIAC 4 and 5 (ClinicalTrials.gov identifier,
NCT01309841 and NCT01323790, respectively)
was to evaluate the response of patients over a
12-week treatment period (see ‘‘Introduction’’),
and the EQ-5D as an exploratory analysis. For
these analyses, the data from the naloxegol
25 mg and placebo arms in the two trials were
pooled, as the studies were of replicate design;
both enrolled outpatients with non-cancer pain,
aged 18–84, and were designed to ensure that
C50% of the patients randomized were LIR at
baseline. Across the two trials all arms had
similar demographic and clinical characteristics
enabling pooling, and this consistency was
present in both the overall and LIR populations
[38]. Moreover, the EQ-5D scores across trials
were similar. In KODIAC 4, the placebo arm had
a mean (with standard deviation) of 0.55 (0.31)
and for naloxegol 25 mg of 0.60 (0.26). In
KODIAC 5, the placebo arm had a baseline
EQ-5D of 0.57 (0.29) and in the naloxegol
25 mg arm of 0.54 (0.31). Across trials the
baseline EQ-5D was 0.56 (0.29) for the placebo
arm and 0.57 (0.29) for the naloxegol 25 mg
arm. KODIAC 4 and 5 were supplemented with
data from KODIAC 7 (ClinicalTrials.gov
identifier, NCT01395524), a 12-week extension
study of patients completing the KODIAC 4
study, designed to assess the maintained efficacy
and safety of naloxegol 12.5 mg and 25 mg in
comparison with placebo in patients with OIC
and non-cancer related pain.
Measures
The analysis was based upon the population of
patients who were LIR, a subset of
intent-to-treat population [37], in
correspondence with the EU label. These
patients were those who had reported taking
at least one laxative class for a minimum of four
days within the two-week period prior to the
screening visit concurrent with at least
moderately severe symptoms of OIC (i.e.,
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incomplete bowel movements, hard stools,
straining, or false alarms).
In this analysis, OIC was defined as having
fewer than 3 SBMs per week in any of the
2 weeks in the preceding 4-week rolling period.
Non-OIC was defined as having 3 or more SBMs
per week in at least 3 weeks out of the preceding
4-week rolling period. Patients with insufficient
data where an OIC or non-OIC response could
not be determined were excluded from the
analyses. This definition varied from the
primary end point used in the trials (see
introduction), which required responders to
not only achieve a certain number of SBMs per
week, but also a minimum change in the
number of SBMs per week. This simplified the
analysis, allowing estimates of utility based on
constipation status, rather than change in that
status. Data to measure OIC status were
available at each of Weeks 4–12 in the
KODIAC 4 and 5 studies. Data on OIC status
was not collected in KODIAC 7.
Health state utility was measured using the
EQ-5D. First, the EQ-5D, a generic QoL
instrument, was collected in all three trials.
The EQ-5D is a self-administered, generic
assessment tool developed by the EuroQol
Group, a network of international research
teams, and consists of questions on five
dimensions of health (i.e., mobility, self-care,
pain/discomfort, usual activities, and anxiety/
depression). The questionnaire was completed
by patients at baseline, Week 4, and Week 12 in
the KODIAC 4 and 5 studies and Weeks 16 and
24 in the KODIAC 7 study. Patient responses to
the EQ-5D questionnaire were converted into
utility values on a 0–1 scale, where 0 represents
death and 1 represents perfect health, using a
tariff estimated from surveys of the UK general
population [39] and in accordance with the
recommendation of the National Institute for
Health and Care Excellence.
Analyses
The objective of the analysis was to estimate the
impact of naloxegol 25 mg (from here on
referred to as ‘naloxegol’) on the health state
utility of LIR patients. This encompasses
estimating how EQ-5D utility index scores
(from here on referred to as ‘utility score’) and
EQ-5D domain responses varied with treatment
(naloxegol vs placebo), OIC status, and over
time. To compare variables, t tests were run on
continuous variables and Fisher’s exact tests
were run on categorical variables, with no
multiple testing corrections being undertaken.
For such analyses, we assessed the absolute score
differences between the arms at week 4 and 12
so to see the added benefits over time of both
naloxegol and in having relief from OIC. A
mixed model repeated measures model with
random intercepts was used to predict the
change from baseline in utility score over
time. Specifically, changes in utility score were
estimates at Weeks 4 and 12. Predictors tested in
the model were: time (weeks), age, gender, race,
body mass index, duration of opioid use,
treatment, baseline utility, and OIC status. To
account for the possibility that the impact of
treatment on utility may vary over time, a
treatment-time interaction variable was also
included in the model. The final model
included variables relevant to the objectives of
the paper; OIC status, treatment, and
time-treatment interaction, plus other
variables whose association with the change in
utility score was statistically significant (p\0.1)
in univariate regression models. The model was
performed using SAS version 9.4, SAS Institute
Inc, Cary, NC.
The studies were conducted in accordance
with the Declaration of Helsinki of 1964, as
revised in 2013, and the International
Conference on Harmonisation. An ethics
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committee or institutional review board at each
study site approved the final study protocol and
informed consent form. All patients provided
written informed consent at screening, before
any study procedures were performed.
RESULTS
The baseline characteristics of LIR patients in
KODIAC 4 and KODIAC 5 are reported in
Table 1.
Utility among LIR patients in the placebo
arm was demonstrably lower than among
patients in naloxegol arm at Week 12 and
when pooling across Weeks 4 and 12 (Table 2).
Relative to placebo, the improvement in health
state utility associated with treatment with
naloxegol was 0.08 (p\0.05) at Week 12.
Table 3 shows how patient responses to the
five separate dimensions of the EQ-5D varied
with treatment in the LIR population. Higher
proportions of patients with ‘‘Moderate’’ or
‘‘Severe’’ problems were consistently observed
with placebo across the five dimensions with
most notable improvements relative to placebo
in the mobility and anxiety/depression
domains.
Figure 1 shows the impact of treatment on
the domains of the EQ-5D over the 12 weeks of
the KODIAC 4 and 5 trials combined. A general
trend was demonstrated in both treatment and
placebo arms, with increases in the proportion
of patients reporting ‘‘no problems’’, and a drop
in the proportion of patients reporting ‘‘some
problems’’. The increase in the proportion of
patients who had ‘‘no problems’’ was
consistently greater for naloxegol patients
than placebo patients.
Table 4 evaluates if a patient’s OIC status
results in a difference in health state utility. It
shows that there is a substantial utility gain
associated with relieving OIC of 0.07
(p = 0.0025).
The effect of treatment and OIC status on
utility score, which was identified in Tables 2
and 4, respectively, are likely to be related.
Table 5, below, presents the mean utility score
of patients when segregated by treatment, time
and OIC status.
Table 5 supports the observation that by
Week 12, health state utility improves as a
result of treatment with naloxegol. There is a
health state utility difference of 0.07 (0.67 vs.
0.60) between naloxegol and placebo patients
who are non-OIC at week 12, and a health state
utility difference of 0.06 (0.60 vs. 0.54) between
naloxegol and placebo patients who are OIC at
Week 12. However, this difference in utility
between treatment groups is no longer
statistically significant when the change in
OIC status is considered. To further examine
this time and treatment effect, a regression
analyses was undertaken.
Table 6 shows how responses to the five
separate dimensions of the EQ-5D varied with
treatment and OIC status in the LIR population.
In Table 3, which did not distinguish between
OIC status following treatment, there was a
statistically significant impact of treatment on
anxiety/depression, and a borderline statistically
significant impact on mobility. These treatment
impacts are no longer observed in patients who
are still constipated after treatment. However,
the treatment impact is still observed in patients
who are non-OIC after treatment, suggesting
that naloxegol may reduce anxiety/depression
and improve mobility, over and above any
impact on these dimensions reflected in the
measure of OIC status.
The analysis reported in Table 7 broadly
supports the observations above that the key
driver of health state utility is OIC status along
with baseline utility, but a time and treatment
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effect does exist. When controlling for other
relevant factors, it is estimated that relieving
OIC is associated with a 0.05 health state utility
improvement. The analysis also identifies a
significant treatment-time interaction effect
(p = 0.024), suggesting that naloxegol at Week
12 generates a utility improvement over and
above its impact on OIC status.
Impact of treatment on health state utility
was also captured in KODIAC 7. Table 8
suggests that the impact of treatment
observed at 12 weeks is maintained to Week
16, though this impact is minimally observed
at Week 24. It is important to note that these
observations should be treated cautiously; they
are based on the subset of participants who
Table 1 Baseline patient and study characteristics (LIR population)
Characteristic Placebo (N5 238) Naloxegol (N5 241)
Study
KODIAC 4, n (%) 118 (49.58) 117 (48.55)
KODIAC 5, n (%) 120 (50.42) 124 (51.45)
Age (years), mean (SD) 53.23 (11.03) 53.41 (11.03)
Sex (females), N (%) 151 (63.45) 150 (62.24)
BMI C 30 kg/m2, N (%) 117 (49.16) 115 (47.92)
Opioid duration (months), mean (SD) 43.03 (47.10) 41.32 (43.55)
Opioid typea
Strong, n (%) 160 (67.23) 176 (73.03)
Weak, n (%) 78 (32.77) 65 (26.97)
Opioid medicationb
Morphine 68 (28.45) 59 (24.48)
Oxycodone 55 (23.01) 64 (26.56)
Hydrocodone ? Paracetamol 63 (26.36) 54 (22.41)
EQ-5D utility score, mean (SD) 0.56 (0.29) 0.57 (0.29)
EQ-5D dimensions
Subjects reporting no problems
Mobility, n (%) 102 (42.86) 99 (41.08)
Self-care, n (%) 187 (78.57) 184 (76.35)
Usual activities, n (%) 84 (35.29) 94 (39.00)
Pain, n (%) 16 (6.72) 12 (4.98)
Anxiety/depression, n (%) 135 (56.72) 143 (59.34)
BMI body mass index, EQ-5D EuroQol—ﬁve Dimensions, LIR laxative inadequate responders, SD standard deviation
a The deﬁnition of strong and weak opioids follows that of the WHO [40]
b Top three opioid medications ranked by total use across KODIAC 4 and 5 LIR patients
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Table 2 Impact of treatment on utility score (KODIAC 4 and 5 trials)
Placebo Naloxegol p value*
N Mean (SD) N Mean (SD)
Week 4 229 0.59 (0.30) 227 0.60 (0.28) 0.6345
Week 12 194 0.57 (0.32) 186 0.65 (0.29) 0.0149
Week 4 and 12 combined 423 0.58 (0.31) 413 0.62 (0.29) 0.0436
EQ-5D EuroQol—ﬁve dimensions, OIC opioid-induced constipation, SD standard deviation
* T test was used for the comparison
Table 3 Impact of treatment on EQ-5D domains at week 12
EQ-5D dimension Category Placebo (n 5 186) Naloxegol (n5 194)
Mobility No problems 90 (46.4) 107 (57.5)
Some problems 103 (53.1) 78 (41.9)
Severe problems 1 (0.5) 1 (0.5)
Fisher Exact Test p value 0.051
Self-Care No problems 156 (80.4) 153 (82.3)
Some problems 37 (19.1) 33 (17.7)
Severe problems 1 (0.5) 0 (0.0)
Fisher Exact Test p value 0.842
Usual activities No problems 78 (40.2) 90 (48.4)
Some problems 107 (55.2) 88 (47.3)
Severe problems 9 (4.6) 8 (4.3)
Fisher Exact Test p value 0.276
Pain No problems 22 (11.3) 33 (17.7)
Some problems 131 (67.5) 124 (66.7)
Severe problems 41 (21.1) 29 (15.6)
Fisher Exact Test p value 0.120
Anxiety/depression No problems 112 (57.7) 140 (75.3)
Some problems 72 (37.1) 40 (21.5)
Severe problems 10 (5.2) 6 (3.2)
Fisher Exact Test p value 0.001
EQ-5D EuroQol—ﬁve dimensions
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completed the KODIAC 4 trial and were rolled
into the KODIAC 7 extension study.
Consequently, the sample is small and subject
to selection bias.
DISCUSSION
These analyses demonstrate the utility benefits
of treating OIC in LIR patients with naloxegol
25 mg. On a scale of 0–1, where 0 represents
death and 1 perfect health, patients treated with
this, saw a 0.08 improvement in health state
utility at 12 weeks after treatment, relative to
placebo. Recent studies concluded that opioid
antagonists improve OIC-related symptoms. For
instance, there is evidence that naloxone in
combination with oxycodone generates
improvements in the Bowel Function Index
[41]. The current study adds to this literature by
observing health state utility improvements in
the EQ-5D. As well as being a validated
Fig. 1 Change in percent of patients in EQ-5D domains, baseline to week 12 (KODIAC 4 and 5)
Table 4 EQ-5D utility score by OIC status (KODIAC 4
and 5 trials, pooled naloxegol and placebo arms pooled
across weeks 4 and 12)
EQ-5D
N Mean SD p value*
Non-OIC 438 0.63 0.29 0.0025
OIC 311 0.56 0.30
EQ-5D EuroQol—ﬁve dimensions, OIC opioid-induced
constipation, SD standard deviation
* T test was used for the comparison
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instrument, and providing data compatible
with the needs of those undertaking
cost-utility analysis, the EQ-5D is a generic
instrument which has the advantage of
generating utility estimates comparable with
those generated for many other indications.
Although we have demonstrated an impact
on utility levels, an appropriate, indication
specific, estimate of a minimum important
difference (MID) is not in the published
literature. Analyses in patients with OIC need
to be undertaken to define this. Although
Coretti et al. [42] concludes that there is a
great amount of heterogeneity in estimates of
MIDs due to variations in study populations
and methodologies and in the absence of such
an estimate, it is useful to observe that a 0.08
improvement represents a 14% improvement
on the baseline utility of patients in trial, and is
equivalent to the utility loss from the long-term
consequences of a moderate stroke, profound
hearing loss with ringing, or a dislocated
shoulder [43].
When a baseline utility score and OIC status
were controlled for, the effect of treatment
alone on health state utility disappears though
treatment-time effect remains, suggesting that
naloxegol has a lasting impact on utility over
and above its impact on OIC status. This may
point to the limitation of the binary measure of
OIC improvement adopted in the study. The
definition of OIC reflected recognized best
practice, drawing on the Rome III diagnostic
criteria for functional constipation [44].
However, this measure would potentially miss
some of the impact of treatment on health state
utility if there is an improvement in OIC
symptoms and the number of SBMs beyond
that captured by the measure of OIC status. This
caveat is supported by the trial data. In both
KODIAC 4 and KODIAC 5, patients who were
not constipated experienced more SBMs when
on naloxegol than on placebo. Further work
should be undertaken to explore the impact of
changes in numbers of SBMs on utility score.
The analyses also suggest that change in OIC
status is the most impactful driver of the
improvement of OIC treatment on utility.
When other factors are controlled, relieving
OIC is associated with a 0.05 improvement in
health state utility. This estimate of the impact
of OIC on utility is lower than those previously
reported in the literature [26], reflecting the
limitations in the methods adopted in previous
studies and the lack of face validity of their
findings. Nevertheless, even at this lower level,
Table 5 EQ-5D utility scores by treatment, OIC status, and time (KODIAC 4 and 5)
Placebo Naloxegol p values
N Mean (SD) N Mean (SD)
Non-OIC
Week 4 92 0.62 (0.29) 134 0.62 (0.29) 0.9513
Week 12 89 0.60 (0.28) 123 0.67 (0.29) 0.1189
OIC
Week 4 120 0.57 (0.31) 67 0.57 (0.24) 0.8933
Week 12 81 0.54 (0.33) 43 0.60 (0.29) 0.2736
EQ-5D EuroQol—ﬁve dimensions, OIC opioid-induced constipation, SD standard deviation
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Table 6 Responses to EQ-5D dimensions by response status and treatment at week 12
Response EQ-5D dimension Category Placebo (n 5 89) Naloxegol (n 5 123)
Non-OIC Mobility No problems 40 (44.9) 76 (61.8)
Some problems 49 (55.1) 47 (38.2)
Severe problems 0 (0) 0 (0)
p value 0.018
Self-care No problems 74 (83.1) 101 (82.1)
Some problems 15 (16.9) 22 (17.9)
Severe problems 0 (0) 0 (0)
p value 1.000
Usual activities No problems 38 (42.7) 63 (51.2)
Some problems 49 (55.1) 53 (43.1)
Severe problems 2 (2.2) 7 (5.7)
p value 0.171
Pain No problems 9 (10.1) 25 (20.3)
Some problems 64 (71.9) 79 (64.2)
Severe problems 16 (18.0) 19 (15.4)
p value 0.138
Anxiety/depression No problems 52 (58.4) 99 (80.5)
Some problems 35 (39.3) 21 (17.1)
Severe problems 2 (2.2) 3 (2.4)
p value \0.001
Response EQ-5D dimension Category Placebo (n 5 81) Naloxegol (n 5 43)
OIC Mobility No problems 38 (46.9) 21 (48.8)
Some problems 43 (53.1) 22 (51.2)
Severe problems 0 (0) 0 (0)
p value 0.852
Self-care No problems 62 (76.5) 35 (81.4)
Some problems 19 (23.5) 8 (18.6)
Severe problems 0 (0) 0 (0)
p value 0.650
Usual activities No problems 31 (38.3) 16 (37.2)
Some problems 45 (55.6) 26 (60.5)
Severe problems 5 (6.2) 1 (2.3)
p value 0.733
Pain No problems 9 (11.1) 5 (11.6)
Some problems 51 (63.0) 29 (67.4)
Severe problems 21 (25.9) 9 (20.9)
p value 0.847
Anxiety/depression No problems 47 (58.0) 30 (69.8)
Some problems 29 (35.8) 12 (27.9)
Severe problems 5 (6.2) 1 (2.3)
p value 0.409
p values are obtained from Fisher Exact test
EQ-5D EuroQol—ﬁve dimensions, OIC opioid-induced constipation
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the impact of OIC on utility points to an
important burden of illness and the need for
effective treatments for patients with OIC.
The analysis of changes in the dimensions of
the EQ-5D instrument suggest that the utility
gain associated with naloxegol is primarily a
result of improved mobility and reduced
anxiety/depression, due to relief of OIC
symptoms. No statistically significant change
in the pain dimension of the EQ-5D instrument
was observed, which was not unexpected given
naloxegol being a treatment for OIC. However,
a disadvantage of the EQ-5D is that its health
state descriptive system is not always designed
to be sensitive to certain medical conditions
[45]. The EQ-5D describes only 5 dimensions,
and has been shown to be less sensitive to
conditions, such as vision problems [46–50],
diabetes, and arthritis. This could potentially
lead to underestimation of the impact of
indications on utility. For instance, the EQ-5D
may miss the impact of OIC on social
functioning. This concern has often led to the
use of disease-specific instruments and mapping
exercises to create utility scores based upon
these disease specific instruments. One disease
specific instrument developed for constipation
is the Patient Assessment of Constipation
Quality of Life questionnaire. This provides a
brief but comprehensive assessment of the
burden of constipation on patients’ everyday
functioning and well-being [51]. It is the most
frequently used instrument to assess health
related quality of life in patients with chronic
constipation and is validated in this disease, but
has not been specifically validated in patients
with OIC [22].
Finally, it should be reiterated that the
EQ-5D was not the primary endpoint in the
KODIAC trials. Consequently, the trials were
Table 7 MMRM for change from baseline in utility score (KODIAC 4 and 5)a
Estimate SE Pr > |t|
Intercept 0.2945 0.0290 \0.0001
Baseline utility score -0.5049 0.0380 \0.0001
Time (Week 12 vs. Week 4) -0.0229 0.0210 0.278
Treatment (naloxegol vs. placebo) -0.0137 0.0260 0.597
OIC status (non-OIC vs. OIC)b 0.0514 0.0203 0.012
Interaction (treatment 9 time) (naloxegol at Week 12 vs. other) 0.0683 0.0300 0.024
MMRM mixed model repeated measures, OIC opioid-induced constipation, SE standard error, Pr[|t| probability that the
estimate is greater than t statistic
a Age, gender, race, BMI, and duration of opioid use were tested but not included in the model due to lack of signiﬁcance
b Observed at weeks 4 and 12, to correspond with the observation of change in utility score
Table 8 EQ-5D utility scores of patients in each
treatment group
Placebo Naloxegol p values
N Mean (SD) N Mean (SD)
Week 4a 40 0.55 (0.31) 44 0.63 (0.24) 0.2196
Week 12a 41 0.52 (0.34) 43 0.66 (0.28) 0.0354
Week 16b 40 0.53 (0.34) 39 0.70 (0.23) 0.0147
Week 24b 38 0.59 (0.33) 37 0.61 (0.29) 0.7195
EQ-5D EuroQol—ﬁve dimensions, OIC opioid-induced
constipation, SD standard deviation
a KODIAC 4 data for participants who continued to be
observed in KODIAC 7
b KODIAC 7 data
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not prospectively powered for these endpoints,
and we need to be cautious when using
secondary and exploratory endpoints to assess
the impact of treatment. However, this caution
should be offset against the positive result
obtained on the primary endpoint, response,
and the fact that response is a key driver of the
improvement in health state utility observed
with naloxegol.
CONCLUSION
Treatment of chronic pain with opioids is
associated with many challenges, with OIC
being an important factor due to its impact
upon daily activities and health state utility.
These analyses suggest that treatment with
naloxegol improves patients’ health state
utility, and this is primarily driven by a
change in the status of OIC.
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